Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vigil Neuroscience, Inc. - Common Stock (NQ:VIGL)

7.880 UNCHANGED
Streaming Delayed Price Updated: 10:40 AM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 3 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasdaq – VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Peraso Inc. (NASDAQ: PRSO) Aligned with BEAD Act’s $42.45B Broadband Mission: Driving Scalable Wireless Innovation
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Synergy CHC Corp. (NASDAQ: SNYR) Eyes Roth Capital’s Target Amid Profit Streak, Global Expansion & Sector Momentum
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
From Kahn Swick & Foti, LLC
Via Business Wire
Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
VIGL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Vigil Neuroscience, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.